Alx oncology reports topline data from aspen-06 phase 2 trial demonstrating evorpacept improves tumor response in patients with her2-positive gastric cancer

South san francisco, calif., july 31, 2024 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or the “company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today announced topline data from its phase 2 aspen-06 clinical trial. the trial demonstrated clinically meaningful improvements in overall response rate and duration of response among patients with previously treated her2-positive advanced gastric cancer (gc) or gastroesophageal junction (gej) cancer.
ALXO Ratings Summary
ALXO Quant Ranking